
Janssen Drugs /Indication



Across

- 1. Indicated for several disease states such as Crohn's Disease, RA,Ulcerative Colitis, etc.
- **2.** Active psoriatic arthritis (PsA) Active ankylosing spondylitis (A
- **5.** Indicated for the treatment of adult patients with active psoriatic arthritis, and Crohn's Disease.
- **9.** Indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen.
- **12.** In combination with other antiretroviral agents (ARVs), is indicated for the treatment of human immunodeficiency virus (HIV-1) infection in patients.
- 13. Indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in ARV treatment-experienced patients ages 6 years and older,

- **15.** Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- **16.** Indicated for the treatment of adults with moderate to severe plaque psoriasis
- 17. Indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection
- **18.** Indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF).
- 19. Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both canagliflozin and metformin is appropriate.

<u>Down</u>

3. Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both canagliflozin and metformin is appropriate.

- **4.** Indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naïve patients 12 years of age and older
- **6.** Indicated for the treatment of patients with Multicentric Castleman's Disease
- 7. Moderately to severely active rheumatoid arthritis (RA) in combination with methotrexate
- **8.** Indicated for with metastatic castration-resistant prostate cancer (mCRPC) with metastatic high-risk castration-sensitive prostate cancer (CSPC)
- **10.** Indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer.
- 11. Indicated for the treatment of anemia due to chronic kidney disease (CKD),
- **14.** For the treatment of patients with newly diagnosed multiple myeloma